Terms & Conditions of Sale
This Terms and Conditions of Sale (this "Agreement") is made effective as of October 06, 2020, by PAK BioSolutions, Inc., of 8301 Arlington Blvd Suite T6, Fairfax, Virginia 22031, ("PAK BioSolutions").
1. ITEMS PURCHASED. PAK BioSolutions agrees to sell, and Buyer agrees to buy, the products (the “Goods”) in accordance with the terms and conditions of this Agreement.
2. PRODUCT STANDARDS. The Goods shall comply with PAK BioSolutions product specifications and drawings.
3. TITLE/RISK OF LOSS. Buyer shall pay reasonable shipping costs in accordance with its shipping instructions, but the seller shall be responsible for packaging, shipping and safe delivery and shall bear all risk of damage or loss until the goods are delivered to the Buyer’s address within the continental United States (products shall be FOB destination). International deliveries shall be EXW (ex-works).
4. PAYMENT. Payment shall be made to 8301 Arlington Blvd Suite T6, Fairfax, Virginia 22031.
Buyer agrees to pay the invoiced amount within thirty (30) days from Buyer’s receipt of invoice. If any invoice is not paid when due, interest will be added to and payable on all overdue amounts at a rate of 1.5 percent per month, or the maximum percentage allowed under applicable laws, whichever is less. Buyer shall pay all costs of collection, including without limitation, reasonable attorney fees.
In addition to any other right or remedy provided by law, if Buyer fails to pay for the Goods when due, PAK BioSolutions has the option to treat such failure to pay as a material breach of this Agreement, and may cancel this Agreement and/or seek legal remedies as described below under “Remedies on Default.”
5. DELIVERY. PAK BioSolutions will arrange for delivery within the continental United States.
6. PAYMENT OF TAXES. Buyer agrees to pay all taxes of every description, federal, state, municipal, customs duties and import/export fees that arise as a result of this sale, excluding income taxes.
7. WARRANTIES. PAK BioSolutions warrants to Buyer that the Goods will conform substantially to the applicable drawings and product specifications when used in accordance with their applicable instructions for a period of one year from shipment of the Products.
PAK BIOSOLUTIONS SHALL IN NO EVENT BE LIABLE FOR ANY INCIDENTAL, SPECIAL, OR CONSEQUENTIAL DAMAGES OF ANY NATURE, EVEN IF PAK BIOSOLUTIONS HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
PAK BioSolutions’s liability, if any, for defective Goods, is limited to replacement, repair or refund of the defective Goods, at PAK BioSolutions option.
8. INSPECTION. Buyer, upon receiving possession of the Goods, shall have 90 days to inspect the Goods to determine if the Goods conform to the requirements of this Agreement. If Buyer, in good faith, determines that all or a portion of the Goods are non-conforming, Buyer may return the Goods to PAK BioSolutions at PAK BioSolutions’s expense. Buyer must provide written notice to PAK BioSolutions of the reason for rejecting the Goods. PAK BioSolutions will have 90 days from the return of the Goods to remedy such defects under the terms of this Agreement.
9. DEFAULT. The occurrence of any of the following shall constitute a material default under this Agreement:
a. The failure to make a required payment when due.
b. The insolvency or bankruptcy of either party.
c. The subjection of any of either party’s property to any levy, seizure, general assignment for the benefit of creditors, application or sale for or by any creditor or government agency.
d. The failure to make available or deliver the Goods in the time and manner provided for in this Agreement.
10. REMEDIES ON DEFAULT. In addition to any and all other rights a party may have available according to law, if a party defaults by failing to substantially perform any provision, term or condition of this Agreement (including without limitation the failure to make a monetary payment when due), the other party may terminate the Agreement by providing written notice to the defaulting party. This notice shall describe with sufficient detail the nature of the default. The party receiving such notice shall have 30 days from the effective date of such notice to cure the default(s). Unless waived by a party providing notice, the failure to cure the default(s) within such time period shall result in the automatic termination of this Agreement.
11. FORCE MAJEURE. If performance of this Agreement or any obligation under this Agreement is prevented, restricted, or interfered with by causes beyond either party’s reasonable control (“Force Majeure”), and if the party unable to carry out its obligations gives the other party prompt written notice of such event, then the obligations of the party invoking this provision shall be suspended to the extent necessary by such event. The term Force Majeure shall include, without limitation, acts of God, fire, explosion, vandalism, storm or other similar occurrence, orders or acts of military or civil authority, or by national emergencies, insurrections, riots, or wars, or strikes, lock-outs, work stoppages, or supplier failures. The excused party shall use reasonable efforts under the circumstances to avoid or remove such causes of non-performance and shall proceed to perform with reasonable dispatch whenever such causes are removed or ceased. An act or omission shall be deemed within the reasonable control of a party if committed, omitted, or caused by such party, or its employees, officers, agents, or affiliates.
12. DISPUTE RESOLUTION. Any controversies or disputes arising out of or relating to this Contract shall be resolved by binding arbitration in accordance under the rules of the American Arbitration Association. The parties shall select a mutually acceptable arbitrator knowledgeable about issues relating to the subject matter of this Contract. The arbitrator(s) shall not have the authority to modify any provisions of this Contract or to award punitive damages. The arbitrator(s) shall have the power to issue mandatory orders and restraint orders in connection with the arbitration. The decision rendered by the arbitrator(s) shall be final and binding on the parties, and judgment may be entered in conformity with the decision in any court having jurisdiction. During the continuance of any arbitration proceeding, the parties shall continue to perform their respective obligations under this Contract.
Both parties acknowledge that during the course of this Agreement, each may obtain confidential information regarding the other party’s business. Both parties agree to treat all such information and the terms of this Agreement as confidential and to take all reasonable precautions against disclosure of such information to unauthorized third parties during and after the term of this Agreement. Upon request by an owner, all documents relating to the confidential information will be returned to such owner.
14. PATENT OR TRADEMARK.
Nothing in this Agreement shall be deemed a transfer or grant of a license of any existing intellectual property rights from PAK BioSolutions to the Buyer, or from transferring, assigning, or selling PAK BioSolutions technology to any third party.
15. ASSIGNMENT. Neither party may assign or transfer this Agreement without prior written consent of the other party, which consent shall not be unreasonably withheld.
16. ENTIRE AGREEMENT. This Agreement contains the entire agreement of the parties regarding the subject matter of this Agreement, and there are no other promises or conditions in any other agreement whether oral or written. This Agreement supersedes any prior written or oral agreements between the parties.
17. AMENDMENT. This Agreement may be modified or amended if the amendment is made in writing and signed by both parties.
18. SEVERABILITY. If any provision of this Agreement shall be held to be invalid or unenforceable for any reason, the remaining provisions shall continue to be valid and enforceable. If a court finds that any provision of this Agreement is invalid or unenforceable, but that by limiting such provision it would become valid and enforceable, then such provision shall be deemed to be written, construed, and enforced as so limited.
19. WAIVER OF CONTRACTUAL RIGHT. The failure of either party to enforce any provision of this Agreement shall not be construed as a waiver or limitation of that party’s right to subsequently enforce and compel strict compliance with every provision of this Agreement.
20. APPLICABLE LAW. This Agreement shall be governed by and construed according to the laws of the State of Virginia without reference to its conflicts of law principles.
NOW AVAILABLE Pilot Scale PAK System
Demo, lease or purchase The PAK System continuous manufacturing equipment. Receive your custom quote now.Request quote
April 16-18, 2024
April 9-12, 2024
March 26-28, 2024
March 17-22, 2024
March 17-21, 2024
Job Description: PAK BioSolutions is hiring a Senior Sales Specialist to support and develop the growth of the company. This…
Job Description: PAK BioSolutions is hiring a Quality Manager to oversee the company’s quality systems. This role will report to…
C.J. Hall is an Engineer at PAK BioSolutions, where he specializes in sourcing, R&D, and system operation. This past fall,…
Vienna, VA – PAK BioSolutions has entered the BioTools Innovator Best Video Competition. There are 17 entries this year, and…
We owe basic worker’s rights and safe working conditions to the American Labor Movement, which we celebrate with Labor Day…
Vienna, VA – PAK BioSolutions has been given the 2023 Top Virginia Employers for Interns Award by the Virginia Talent…
Sustainability went mainstream for businesses back in 2021, according to the Harvard Business Review. To get on track for goals…
This summer, PAK BioSolutions welcomed two undergraduate interns into the office. Julia Feldhaus is an upcoming third year at University…
Vienna, VA – PAK BioSolutions has been chosen as a finalist for the Biotools Innovator 2023 program. This program serves…
Huda Khawar is a Laboratory Technician at PAK BioSolutions. As a Lab Technician, she is responsible for the assembly of…
Vienna, VA – PAK BioSolutions, Inc. has announced a Continuous Purification Course to take place the week of August 28-September…
Kevin Hill-Byrne is the Co-Founder and CTO of PAK BioSolutions. As CTO, he is responsible for overseeing new product development…
Vienna, VA – PAK BioSolutions has been awarded the Biotech Innovation Award for INTERPHEX 2023. The show, taking place April…
Vienna, VA – In cooperation with AstraZeneca, PAK BioSolutions has published a new article in the latest issue of Biotechnology…
Abstract Next‐generation manufacturing (NGM) has evolved over the past decade to a point where large biopharmaceutical organizations are making large…
Job Description: PAK BioSolutions is seeking a Software Engineer to develop new tools, algorithms, and control strategies related to the…
Vienna, VA – PAK BioSolutions, Inc. (PAK BioSolutions or the Company), a biotechnology company developing products for the continuous purification…
Fairfax, VA – PAK BioSolutions has been awarded its first patent for a “Therapeutic Protein Flow Kit for a Continuous…
How does a PAK BioSolutions purification suite revolutionize the manufacture of pharmaceuticals? With a correctly-designed continuous purification process, a PAK…
Significant cost savings are commonly advertised for continuous biopharmaceutical processes, but where they come from is not always immediately apparent….
What exactly is productivity? At PAK BioSolutions, we define productivity for a biopharmaceutical process, whether batch or continuous, as the…
Fairfax, VA – PAK BioSolutions Inc. was featured in the latest edition of Genetic Engineering & Biotechnology News (GEN). The…
Fairfax, VA – PAK BioSolutions, Inc. received its first automated system for continuous purification of biopharmaceuticals from the automation integrators…
Alexandria, VA – A patent application has been submitted for a solid, single use flow kit designed for purification of…
Fairfax, VA – PAK BioSolutions, Inc. was recently founded and today welcomes on board Vice-President and co-founder Kevin Hill-Byrne. The…
Abstract The concept of continuous manufacturing has gained significant interest from the biopharmaceutical industry over the past several years. Benefits…